Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982552 · ClinicalTrials.gov registry record
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
A clinical trial, sponsored by LEO Pharma.
- Completed
- Registry status
- 147
- Enrollment target
NCT01982552 is a clinical trial that has completed, run by LEO Pharma. The registered enrollment target is 147 participants.
The verdict
NCT01982552 has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
Study Summary
The purpose of this study is to document quality of life, patient satisfaction, effect on itching, and control of psoriasis vulgaris associated with use of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% for treatment of plaque psoriasis under real-life conditions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982552
The ClinicalTrials.gov registry entry for NCT01982552 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01982552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982552 about?
NCT01982552 is a clinical study titled "An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life". The purpose of this study is to document quality of life, patient satisfaction, effect on itching, and control of psoriasis vulgaris associated with use of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% for treatment of plaque psoriasis under real-life condit...
What is the current status of trial NCT01982552?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2013-07. Estimated completion is 2014-01.
Who is sponsoring clinical trial NCT01982552?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.